Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna Stock Jumps
Moderna’s Struggles Could Complicate Bird Flu Fight. What It Means for a Potential Vaccine.
Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
US health dept providing Moderna $590 mn to speed mRNA bird flu vaccine
US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, including advancing the company's bird flu vaccine, as fears of a new pandemic grow.
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a $590 million award from the U.S. Health and Human Services Department to accelerate its bird flu vaccine development.
Moderna secures $590M in government funding to develop bird flu vaccine
The U.S. government has awarded Moderna $590 million to help speed up the development of a bird flu vaccine. President Trump ends marathon inauguration day at three inaugural balls José Andrés Says This Is the Best Substitute for Salt Macron announces plan for mobilization of volunteers Real-life “Yellowstone” cowboy went from sleeping in a tent to a building a TV empire New Bears coach Ben Johnson eyeing two former NFL head coaches for his staff in Chicago,
2d
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
1d
on MSN
Why Moderna (MRNA) Stock Is Advancing Today
RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...
7h
Moderna spikes as Oracle’s Larry Ellison touts AI-driven mRNA vaccines
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.
5h
InnovationRx: The Impact Of Trump’s Withdrawal From The WHO And His Other Healthcare Orders
Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA approved.
2d
on MSN
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...
9d
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback